TaiGen signs Russian licensing deal for novel antibiotic
This article was originally published in Scrip
Executive Summary
Taiwanese firm TaiGen Biotechnology has signed an exclusive deal with Russian pharma R-Pharm to develop and commercialize TaiGen's novel antibiotic Taigexyn (nemonoxacin).